OMV-Vacc
Our proprietary vaccine platform technology
Outer Membrane Vesicles (OMVs) are naturally released spherical nanoparticles by gram-negative bacteria. These non-replicating vesicles carry strong immune potentiators such as PAMPs and trigger an immune response, enabling protective immunity.
AdJane has genetically engineered OMVs for enhanced safety, increased yield, and long term stability. Our unique OMV-Vacc platform, backed by 7 patent families, has been optimized for scalability and versatility, proven as we advance our programs along clinical development.
OMV-Vacc Platform
AdJane’s unique platform technology that will revolutionize the vaccine industry
1. Novel vaccine platform technology
OMV-Vacc is applicable for both bacterial and viral vaccines, administration-route-agnostic” and can be utilized in multivalent vaccine concepts. Our platform ensures broad protection – a key milestone in vaccinology.
2. Strong and durable immunity
After intramuscular or intranasal administration, OMV-Vacc activates the TLR4 pathway, inducing a balanced, strong, and durable immune response. ADA includes cellular (Th1), humoral (Th2), and mucosal (Th17) immunity.
3. Safe and well-tolerated
Clinical phase 1 study confirm OMV-Vacc’s excellent safety profile with no adverse effects. The modified Neisseria meningitidis bacteria are specifically engineered to reduce LPS toxicity while preserving adjuvating properties to trigger a natural immune response.
4. Scalable, high yield, and excellent stability
Our proprietary GMP manufacturing process is optimized for flexible, high-yield, and consistent production of OMVs, that demonstrate exceptional 5+ years stability under standard cold-chain conditions.